Memantine (Ebixa®) in the later stages of dementia
- 1 November 2003
- journal article
- review article
- Published by Mark Allen Group in Hospital Medicine
- Vol. 64 (11) , 654-657
- https://doi.org/10.12968/hosp.2003.64.11.2346
Abstract
Memantine is the first agent licensed for the treatment of moderate to severe Alzheimer's disease. It is an N-methyl D-aspartate (NMDA) receptor antagonist which reduces glutamatergic excitotoxicity. Benefits are seen in cognitive, functional and global measures in both outpatients and nursing home residents. Prospective health economic benefits have been reported.Keywords
This publication has 16 references indexed in Scilit:
- Memantine in Moderate-to-Severe Alzheimer's DiseaseNew England Journal of Medicine, 2003
- Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapyInternational Clinical Psychopharmacology, 2003
- MemantineDrugs & Aging, 2003
- Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer??s DiseasePharmacoEconomics, 2003
- Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular DementiaStroke, 2002
- Glutamate and psychiatric disordersAdvances in Psychiatric Treatment, 2002
- Evaluation of memantine for neuroprotection in dementiaExpert Opinion on Investigational Drugs, 2000
- Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical dataNeuropharmacology, 1999
- Assessment of the severely impaired patient: Description and validation of a new neuropsychological test battery.Psychological Assessment, 1990
- “Mini-mental state”Journal of Psychiatric Research, 1975